glp-1 gip medication long term effects muscle loss agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis Exploring the Side Effects of

GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1

20C temperature-controlled storage Held in stock in our own UK facility Same-day dispatch on orders before cut-off FAQ Frequently asked questions Is KLOW third-party tested for purity?+ What is KLOW studied for in the laboratory?+ How should KLOW be stored and handled?+ Do you ship KLOW across the UK?+ Is KLOW for human or animal use?+

Weve moved quickly to make that available to you and your clients

Cagrilintide monotherapy: 11.8% mean weight loss vs 2.3% placebo

Behav Pharmacol 2017;28:112-23

Ismail R, Bocsik A, Katona G, Grf I, Deli MA, Cska I